DURHAM, N.C., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, will host a virtual webinar to announce top line data results from its Phase 2/3 V005 vascular trauma clinical trial.

DURHAM，N.C.，2023年9月11日（GLOBE NEWSWIRE）-Humacyte，Inc。（纳斯达克股票代码：HUMA），一家临床阶段生物技术平台公司，以商业规模开发普遍植入式生物工程人体组织，将举办虚拟网络研讨会，公布其2/3期V005血管创伤临床试验的顶级数据结果。

The V005 trial evaluated the HAV, an off-the-shelf, universally implantable bioengineered human tissue, in vascular trauma repair. The event will also feature Dr. Michael Curi (Rutgers University), who will discuss the unmet clinical need in vascular trauma, and the use of the HAV as a potential repair solution for patients and soldiers with limb- and life-threatening injuries.

V005试验评估了HAV，一种现成的，普遍可植入的生物工程人体组织，用于血管创伤修复。该活动还将以罗格斯大学的Michael Curi博士为特色，他将讨论血管创伤中未满足的临床需求，以及将HAV用作危及肢体和生命的伤害患者和士兵的潜在修复方案。

Dr. Curi has utilized the HAV and has participated in the V005 clinical trial. The HAV has received priority designation for the treatment of vascular trauma by the U.S. Department of Defense and Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration. A live question and answer session will follow the formal presentations.

Curi博士利用了HAV并参与了V005临床试验。HAV已获得美国国防部和再生医学高级治疗（RMAT）指定的美国食品和药物管理局对血管创伤治疗的优先指定。正式演讲将随后进行现场问答。

Details of the data announcement webinar are as follows: Title:Phase 2/3 V005 Trial Top Line Data AnnouncementDate:Tuesday, September 12, 2023Time:8:00 AM ETWebcast:Webcast Link – Click Here   About HumacyteHumacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine.

数据公告网络研讨会的详细信息如下：标题：第2/3阶段V005试用顶级数据公告日期：2023年9月12日星期二时间：ETWebcast:8:00 AM网络广播链接-点击此处关于HumacyteHumacyte，Inc。（纳斯达克股票代码：HUMA）正在开发一个颠覆性的生物技术平台，以提供普遍植入的生物工程人体组织，先进的组织构造，和旨在改善患者生活和改变医学实践的器官系统。

The company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s initial opportunity is currently in late-stage clinical trials targeting multiple vascular application.

该公司开发和制造无细胞组织，以治疗各种疾病，伤害和慢性病。Humacyte的最初机会目前正处于针对多种血管应用的晚期临床试验中。